Menu
Back to Journals » OncoTargets and Therapy » Volume 10
Original Research
Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 12,861 | Dovepress* | 12,397+ | 1,197 | 13,594 | |
| PubMed Central* | 464 | 230 | 694 | ||
| Totals | 12,861 | 1,427 | 14,288 | ||
| *Since 27 June 2017 | |||||
View citations on PubMed Central and Google Scholar